Alerts will be sent to your verified email
Verify EmailGLENMARK
Glenmark Pharma
|
Alkem Laboratories
|
Aurobindo Pharma
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Number of ANDA's Filed in USA
|
13.0 . | 185.0 . | 865.0 . |
Number of ANDA's Approved By USFDA
|
25.0 . | 160.0 . | 733.0 . |
Domestic Sales Growth - YoY
|
10.3 % | 73.0 % | n/a |
R&D as a % of Total Sales
|
7.3 % | 3.5 % | 4.7 % |
Financials
|
|||
5 yr Average ROE
|
3.99 % | 17.38 % | 12.72 % |
5yr average Equity Multiplier
|
1.78 | 1.39 | 1.46 |
5yr Average Asset Turnover Ratio
|
0.8 | 0.86 | 0.68 |
5yr Avg Net Profit Margin
|
2.85 % | 14.54 % | 12.5 % |
Price to Book
|
6.65 | 5.52 | 1.99 |
P/E
|
78.05 | 28.96 | 19.15 |
5yr Avg Cash Conversion Cycle
|
-150.94 Days | -61.46 Days | -46.37 Days |
Inventory Days
|
32.28 Days | 56.11 Days | 59.62 Days |
Days Receivable
|
32.34 Days | 44.62 Days | 30.33 Days |
Days Payable
|
201.14 Days | 122.42 Days | 121.28 Days |
5yr Average Interest Coverage Ratio
|
4.25 | 24.48 | 43.54 |
5yr Avg ROCE
|
17.54 % | 22.76 % | 15.27 % |
5yr Avg Operating Profit Margin
|
15.96 % | 18.44 % | 19.22 % |
5 yr average Debt to Equity
|
0.38 | 0.18 | 0.19 |
5yr CAGR Net Profit
|
1.54 % | 6.44 % | -8.16 % |
5yr Average Return on Assets
|
2.09 % | 12.47 % | 8.64 % |
Shareholdings
|
|||
Promoter Holding
|
46.65 % | 53.04 % | 51.82 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 17.08 % |
Change in Promoter Holding (3 Yrs)
|
0.0 | -4.1 % | -0.01 % |
Change in Mutual Fund Holding (3 Yrs)
|
9.74 % | 8.82 % | 9.14 % |
Glenmark Pharma
|
Alkem Laboratories
|
Aurobindo Pharma
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|